MRKMerck
$152.55+2.39%Real quote · delayedPharma🏛️ Company factsSEC filings + FINRA official data
Annual revenue $65.0B · latest quarter up 5.1% YoY · profitable (FY net income $18.3B) · short activity within its normal range.
FY revenue
$65.0B
2025-12
Latest Q YoY
+5.1%
FY net income
$18.3B
Diluted EPS
$7.3
Short volume
39.7%
20d avg 41.7% · normal
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-04-30passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-27passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability Medium · 66/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026-$0.13 vs -$0.26+50%
- Mar 2026-$1.28 vs -$1.51+15.23%
- Dec 2025$2.04 vs $2.03+0.49%
- Sep 2025$2.58 vs $2.36+9.32%
This company habitually beats by +18.8% — the next report has to clear that bar to count as good news.
Analyst estimates, not our forecast · not investment advice
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · dot = engine's call · color = outcome, arrow = direction
📜 Call history (newest first
14 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →